Azepane derivatives and methods of treating hepatitis B infections
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
1. A compound, or a pharmaceutically acceptable salt thereof, selected from:
2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
3. A method of treating an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of claim 1 .
4. The method of claim 3 , further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, immunomodulatory agents, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, literature-described capsid assembly modulator, reverse transcriptase inhibitor, a cyclophilin/TNF inhibitor, a TLR-agonist, an HBV vaccine, and a combination thereof.
5. The method of claim 4 , wherein the therapeutic agent is a reverse transcriptase inhibitor, and is at least one of Zidovudine, Didanosine, Zalcitabine, 2′,3′-dideoxyadenosine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, cidofovir, Efavirenz, Nevirapine, Delavirdine, and Etravirine.
6. The method of claim 4 , wherein the therapeutic agent is a TLR agonist, and wherein the TLR agonist is selected from the group consisting of SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl][3-(4-morpholinyl)propyl]amino}methyl)phenyl]acetate).
7. The method of claim 4 , wherein the therapeutic agent is an interferon selected from the group consisting of interferon alpha (IFN-α), interferon beta (IFN-β), interferon lambda (IFN-λ), and interferon gamma (IFN-γ).
8. The method of claim 7 , wherein the interferon is interferon-alpha-2a, interferon-alpha-2b, or interferon-alpha-n1.
9. The method of claim 7 , wherein the interferon-alpha-2a or interferon-alpha-2b is pegylated.
10. The method of claim 7 , wherein the interferon-alpha-2a is pegylated interferon-alpha-2a (PEGASYS).
11. The method of claim 3 , further comprising administering to the individual at least one HBV vaccine, a nucleoside HBV inhibitor, an interferon or any combination thereof.
12. The method of claim 11 , wherein the HBV vaccine is selected from the group consisting of RECOMBIVAX HB, ENGERIX-B, ELOVAC B, GENEVAC-B, and SHANVAC B.
13. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.
20. The compound of claim 1 having the following structural formula:
or a pharmaceutically acceptable salt thereof.